Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely ...
Conservative commentator Megyn Kelly claimed the Pfizer COVID vaccine left her with an auto-immune disorder in explosive new comments on her latest podcast episode Wednesday. Kelly, 54 ...
Note: This story has been corrected to clarify that Talis Biomedical did not file for bankruptcy in 2024 but is no longer an operating company. We regret the error ...
The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday. Patrizia Cavazzoni was formerly director ...
Shares of Pfizer (NYSE:PFE) have delivered negative returns since I started covering the stock and the last four months have not been great either as it is down another 12% since my previous ...
Pfizer wants a piece of the showdown with the world’s biggest medicine. The New York pharma giant — facing an activist investor, shedding multiple parts of … ...
After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., is returning to her previous employer: Big Pharma Pfizer. After ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...
08:07 EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE) See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline ...
It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback